project id: TCGA-BRCA; case submitter id: TCGA-PL-A8LV; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.86; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.11; rna integrity number: 7.2; age at index: 54; days to birth: -19746; ethnicity: not hispanic or latino; gender: female; race: black or african american; vital status: Alive; year of birth: 1959; age at diagnosis: 19746; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic stage: Stage IIIB; ajcc pathologic t: T4; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: -7.0; icd 10 code: C50.9; last known disease status: not reported; morphology: 8510/3; primary diagnosis: Medullary carcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Breast, NOS; synchronous malignancy: No; tissue or organ of origin: Breast, NOS; tumor grade: Not Reported; year of diagnosis: 2013; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 240; days to sample procurement: 0; initial weight: 840.0; oct embedded: false; sample id: 11b582c7-95bf-4a07-8996-ef4d0d4f897e; sample submitter id: TCGA-PL-A8LV-01A; portion submitter id: TCGA-PL-A8LV-01A-21; percent lymphocyte infiltration: 40.0; percent monocyte infiltration: 20.0; percent necrosis: 0.0; percent neutrophil infiltration: 20.0; percent normal cells: 0.0; percent stromal cells: 20.0; percent tumor cells: 80.0; percent tumor nuclei: 80.0;